TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Setting Proper Treatment Expectations

Help prepare your patients

HAE is a genetic and unpredictable lifelong disease, and it's important to set specific goals for therapy. Choosing effective prevention with TAKHZYRO means working with your patient to help prevent and reduce the severity of their HAE attacks—which can help them work toward their treatment goals.1,2

A real TAKHZYRO® patient, Soraya, sitting on a bench outside.

Give TAKHZYRO 2.5 months to reach steady state1

Graph indicating the steady state with TAKHZYRO® that occurs after about 70 days.

Encourage your patients to keep taking TAKHZYRO exactly as you prescribed. TAKHZYRO has a half-life of ~14 days, allowing it to be taken every 2 weeks. Because of this, it can take up to 6 doses (10 weeks) to reach steady state.

Challenge your patient to make a commitment to themselves and TAKHZYRO
Timer icon.
Take each dose as prescribed

TAKHZYRO continues to work as it is taken, so it is important to tell your patients to take each dose as prescribed. Remember to impress upon them to avoid skipping or missing doses.

Warning icon.
Breakthrough attacks

It is normal for patients to experience breakthrough attacks.1,3

It is recommended that patients keep their on-demand medication on hand in case of a breakthrough attack.

Let your patient know that if a breakthrough attack happens, they should not be discouraged. They should keep taking TAKHZYRO as prescribed, and discuss their experience with you.1,3

Calendar icon indicating that TAKHZYRO® is taken every 2 weeks.
Stay the course

Over time, your patient may begin to notice that their attacks are less severe or that they are using their on-demand treatment less. These are signs that TAKHZYRO is working.

Long-term prevention.
Long-term support.

Find suggestions for helping your patients stay on top of preventing HAE attacks with TAKHZYRO.

Keep patients on track
Notepad with a pen icon.

Explore efficacy data

TAKHZYRO is one of the first-line treatments for
long-term prevention of HAE attacks.2

See Efficacy Data

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2022. 2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 3. Wang Y, Marier JF, Kassir N, Chang C, Martin P. Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema. Clin Transl Sci. 2020;13(6):1208-1216. doi:10.1111/cts.12806